microRNA‑10b expression and its correlation with molecular subtypes of early invasive ductal carcinoma

Guo,Chenming; Fu,Minggang; Dilimina,Yilamu; Liu,Sha; Guo,Liying

doi:10.3892/etm.2018.5797

microRNA‑10b expression and its correlation with molecular subtypes of early invasive ductal carcinoma

Authors:
- Chenming Guo
- Minggang Fu
- Yilamu Dilimina
- Sha Liu
- Liying Guo
View Affiliations

Affiliations: Department of Breast Cancer, Digestive and Vascular Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Published online on: January 24, 2018 https://doi.org/10.3892/etm.2018.5797
Pages: 2851-2859
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine whether the expression of microRNA (miR)-10b was correlated with the molecular subtypes of early invasive ductal carcinoma of the breast. In situ hybridization was used to detect the expression of miR‑10b in 193 patients diagnosed with early invasive ductal carcinoma. Immunohistochemistry was performed to evaluate the expression of estrogen receptor (ER)‑α, progesterone receptor (PR) and human epidermal growth factor receptor‑2 (Her‑2). The positive expression rate of miR‑10b in patients with early invasive ductal carcinoma with ER‑α (+) or PR (+) was decreased compared with ER‑α (‑) or PR (‑) patients (P<0.05). Furthermore, the positive expression rate of miR‑10b in patients with Her‑2 (‑) was significantly increased compared with patients that were Her‑2 (+) (P=0.031). The positive expression rate of miR‑10b in the luminal B subtype was significantly decreased compared with that in the luminal A, Her‑2 and basal‑like subtypes (P=0.037). In patients that were identified as miR‑10b (+), the median disease‑free survival time was significantly increased in patients that were ER‑α (+)/PR (+)/Her‑2 (‑) compared with patients that were ER‑α (‑)/PR (‑)/Her‑2 (+) (P<0.05). In addition, the median disease‑free survival time was significantly decreased in Her‑2 overexpression and basal‑like subtypes when compared with luminal A and B subtypes (P<0.05). The molecular subtype was an independent prognostic factor for early invasive ductal carcinoma (odds ratios for luminal B, Basal‑like, and Her‑2 overexpression were 2.900, 5.232 and 4.214, respectively; all P<0.05). Positive expression of miR‑10b may also be a prognostic risk factor (odds ratio >1), though this was not statistically significant (P>0.05). The present findings indicated that miR‑10b‑positive expression was correlated with the expression of ER‑α, Her‑2 and the molecular subtypes of early invasive ductal carcinoma of the breast.

View Figures

View References

1	Simpson PT, Reis-Filho JS and Lakhani SR: Breast pathology: Beyond morphology. Semin Diagn Pathol. 27:91–96. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, et al: NCCN clinical practice guidelinesin oncology: Breast cancer screening and diagnosis. J Natl Compr Cancer Netw. 7:1060–1096. 2009. View Article : Google Scholar
3	Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:pp. 8418–8423. 2003; View Article : Google Scholar : PubMed/NCBI
4	Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Panel members: Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
5	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
6	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicatios. Proc Natl Acad Sci USA. 98:pp. 10869–10874. 2001; View Article : Google Scholar : PubMed/NCBI
7	Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, et al: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 8:R2142007. View Article : Google Scholar : PubMed/NCBI
8	Zhang M, Mo J, Huang P, et al: Clinicopathologic profiles of breast cancer in young women: A report of 85 cases. Chinese Journal of General Surgery. 23:665–669. 2014.
9	Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P and Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 115:423–428. 2009. View Article : Google Scholar : PubMed/NCBI
10	Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
11	Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 23:3676–3685. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM and Gabram SG: High prevalence of triple-negative tumors in an urban cancer center. Cancer. 113:608–615. 2008. View Article : Google Scholar : PubMed/NCBI
13	Carrio M, Arderiu G, Myers C and Boudreau NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res. 65:7177–7185. 2005. View Article : Google Scholar : PubMed/NCBI
14	Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K and Brünner N: Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res. 3:233–239. 1997.PubMed/NCBI
15	Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G and Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER-2/neu receptor status in breast cancer. Breast Cancer Res. 11:R272009. View Article : Google Scholar : PubMed/NCBI
16	Liu Z, Zhu J, Cao H, Ren H and Fang X: miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. Int J Oncol. 40:1553–1560. 2012.PubMed/NCBI
17	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I and Yamashita S: miR-195, miR-455-3p and miR-l0a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
19	Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, et al: miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med. 4:1214–1229. 2012. View Article : Google Scholar : PubMed/NCBI
20	Li Y, Wen J, Tang J, Lai M and Bu H: Breast Cancer Pathology. Eighth. People's Medical Publishing House (China); pp. 373–377. 2005
21	Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131:18–43. 2007.PubMed/NCBI
22	Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M and Bojar H: Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophos-phamide-based Primary (radio-)chemotherapy. Anticancer Res. 25:4615–4621. 2005.PubMed/NCBI
23	Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology. 61 Suppl:S1–S13. 2001. View Article : Google Scholar
24	Stewart BW and Wild CP: World cancer report 2014. Int Age Res Can. 28:17–27. 2014.
25	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM and Guan ZZ: Clinical characteristics and prognosis of different subtypes of breast cancer. Zhonghua Zhong Liu Za Zhi. 30:456–461. 2008.(In Chinese). PubMed/NCBI
27	Prat A and Perou C: Deconstructing the molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011. View Article : Google Scholar : PubMed/NCBI
28	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 iddex, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wang J and Wu JH: The clinical value of endocrine therapy for breast cancer in elderly women. J Can Cont Treat. 23:3852010.
30	Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret JM, Piccart M and Larsimont D: A significant proportion of elderly patients develop hormone-dependant ‘luminal-B’ tumours associated with aggressive characteristics. Crit Rev Oncol Hematol. 67:80–92. 2008. View Article : Google Scholar : PubMed/NCBI
31	Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
32	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
33	Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, Ragoussis J and Harris AL: MicroRNA-10b and breast cancer metastasis. Nature. 455:E8–E9. 2008. View Article : Google Scholar : PubMed/NCBI
34	Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P and Chambon P: Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature. 320:134–139. 1986. View Article : Google Scholar : PubMed/NCBI
35	Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret JM, Piccart M and Larsimont D: A significant proportion of elderly patients develop hormone-dependant ‘luminal-B’ tumours associated with aggressive characterristics. Crit Rev Oncol Hematol. 67:80–92. 2008. View Article : Google Scholar : PubMed/NCBI
36	Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J clin Oncol. 23:619–629. 2005. View Article : Google Scholar : PubMed/NCBI
37	Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol. 25:4423–4430. 2007. View Article : Google Scholar : PubMed/NCBI
38	Yang Q, Chen J, Li HJ, Yu M, Tian CX and Lü Q: Clinical features and prognosis analysis of different breast cancer molecular subtypes. Zhonghua Zhong Liu Za Zhi. 33:42–46. 2011.(In Chinese). PubMed/NCBI